Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,quoteSourceName,triggerable,firstTradeDateMilliseconds,priceHint,regularMarketChange,regularMarketChangePercent,regularMarketTime,regularMarketPrice,regularMarketDayHigh,regularMarketDayRange,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,fullExchangeName,financialCurrency,regularMarketOpen,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,averageAnalystRating,tradeable,currency,exchange,longName,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,shortName,marketState,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeDataDelayedBy,displayName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,DARE,7744004,70522000,7340289,,-9162751,,-9162751,1797637,-25000,-9162926,-9162926,,,,,,0,0,9162926,25000,175,,-9162751,-9162751,95762564,7078406,7744004,1250000,14822410,5741,-87917192,1000000,-107109,350283,9111741,6004890,-107109,412907,14059220,2955425,216043,-1928019.0,13251924.0,1561860.0,13251924.0,1451590.0,-8880.0,-11791454.0,6613.0,-2653589.0,384432.0,,,8054330,en-US,US,EQUITY,Nasdaq Real Time Price,True,1397136600000,4,0.0,0.0,1630503612,1.75,1.76,1.74 - 1.76,1.74,152659,1.75,1.75,0.0,32,361,NasdaqCM,USD,1.75,9285695,3596957,0.805,0.8518519,2.0 - Buy,False,USD,NCM,"Daré Bioscience, Inc.",finmb_423979060,America/New_York,EDT,-14400000,us_market,False,"Dare Bioscience, Inc.",REGULAR,0.945 - 3.85,-2.1,-0.54545456,0.945,3.85,1500508800,1628755203,1636551000,1636983000,-0.789,-0.71,-0.63,-2.777778,0.135,1.5805556,0.16944444,0.10720562,1.6118841,0.13811588,0.08568599,123413504,-2.464789,12.962962,15,0,Daré Bioscience,1.50,65.09%,26.30%,3.8500,0.9450,1.5806,1.6119,9.29M,3.6M,70.52M,,68.86M,3.90%,5.04%,4.79M,0.82,6.95%,6.79%,5.25M,,,,,,0.00%,"Jul 19, 2017",,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-175.69%,-807.19%,,,,-83.33k,-32.85M,-32.52M,-0.7890,,9.11M,0.13,492.46k,6.36,2.34,0.14,-34.72M,-21.58M,Value,92122,Healthcare,16,"DarÃ© Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.",San Diego,858 926 7655,CA,1609372800,United States,http://www.darebioscience.com,86400,3655 Nobel Drive,Biotechnology,Suite 260
t-1,DARE,3258233,70522000,5728206,,-7323644,,-7323644,1940328,-25000,-7693534,-7693534,,,,,,0,0,7693534,25000,369890,,-7323644,-7323644,82106172,7260220,3258233,1672430,10518453,4731,-78754441,1000000,-98229,417858,7660151,6108434,-98229,501520,9599075,301835,1471631,-441825.0,11374540.0,-748089.0,11374540.0,2990684.0,-6841.0,-8377015.0,6410.0,158333.0,-28200.0,,,3490641,en-US,US,EQUITY,Nasdaq Real Time Price,True,1397136600000,4,0.0,0.0,1630503612,1.75,1.76,1.74 - 1.76,1.74,152659,1.75,1.75,0.0,32,361,NasdaqCM,USD,1.75,9285695,3596957,0.805,0.8518519,2.0 - Buy,False,USD,NCM,"Daré Bioscience, Inc.",finmb_423979060,America/New_York,EDT,-14400000,us_market,False,"Dare Bioscience, Inc.",REGULAR,0.945 - 3.85,-2.1,-0.54545456,0.945,3.85,1500508800,1628755203,1636551000,1636983000,-0.789,-0.71,-0.63,-2.777778,0.135,1.5805556,0.16944444,0.10720562,1.6118841,0.13811588,0.08568599,123413504,-2.464789,12.962962,15,0,Daré Bioscience,1.50,65.09%,26.30%,3.8500,0.9450,1.5806,1.6119,9.29M,3.6M,70.52M,,68.86M,3.90%,5.04%,4.79M,0.82,6.95%,6.79%,5.25M,,,,,,0.00%,"Jul 19, 2017",,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-175.69%,-807.19%,,,,-83.33k,-32.85M,-32.52M,-0.7890,,9.11M,0.13,492.46k,6.36,2.34,0.14,-34.72M,-21.58M,Value,92122,Healthcare,16,"DarÃ© Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.",San Diego,858 926 7655,CA,1609372800,United States,http://www.darebioscience.com,86400,3655 Nobel Drive,Biotechnology,Suite 260
t-2,DARE,-1151733,70522000,6638409,,-8441475,,-8441475,1777126,-25000,-8440535,-8440535,,,,,,0,0,8440535,25000,-940,,-8441475,-8441475,70366293,8702445,-1151733,2564553,7550712,4159,-71430797,1000000,-91388,289320,4669467,7660601,-91388,277480,6983912,460168,1021333,-1147799.0,8454761.0,472536.0,8454761.0,-719947.0,21419.0,-9193748.0,6799.0,-246608.0,162799.0,-2379.0,-2379.0,-676689,en-US,US,EQUITY,Nasdaq Real Time Price,True,1397136600000,4,0.0,0.0,1630503612,1.75,1.76,1.74 - 1.76,1.74,152659,1.75,1.75,0.0,32,361,NasdaqCM,USD,1.75,9285695,3596957,0.805,0.8518519,2.0 - Buy,False,USD,NCM,"Daré Bioscience, Inc.",finmb_423979060,America/New_York,EDT,-14400000,us_market,False,"Dare Bioscience, Inc.",REGULAR,0.945 - 3.85,-2.1,-0.54545456,0.945,3.85,1500508800,1628755203,1636551000,1636983000,-0.789,-0.71,-0.63,-2.777778,0.135,1.5805556,0.16944444,0.10720562,1.6118841,0.13811588,0.08568599,123413504,-2.464789,12.962962,15,0,Daré Bioscience,1.50,65.09%,26.30%,3.8500,0.9450,1.5806,1.6119,9.29M,3.6M,70.52M,,68.86M,3.90%,5.04%,4.79M,0.82,6.95%,6.79%,5.25M,,,,,,0.00%,"Jul 19, 2017",,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-175.69%,-807.19%,,,,-83.33k,-32.85M,-32.52M,-0.7890,,9.11M,0.13,492.46k,6.36,2.34,0.14,-34.72M,-21.58M,Value,92122,Healthcare,16,"DarÃ© Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.",San Diego,858 926 7655,CA,1609372800,United States,http://www.darebioscience.com,86400,3655 Nobel Drive,Biotechnology,Suite 260
t-3,DARE,-1385888,70522000,6203753,,-7582808,,-7582808,1353069,-25000,-7581822,-7581822,,,,,,0,0,7581822,25000,-986,,-7582808,-7589671,61712882,9047630,-1385888,3178379,7661742,3360,-62989323,1000000,-112807,328957,5389414,7964666,-112807,348349,6984436,213560,1555307,74823.0,5398582.0,2015755.0,5398582.0,42542.0,672.0,-5356712.0,12499.0,-36427.0,159445.0,-2379.0,-2379.0,-980230,en-US,US,EQUITY,Nasdaq Real Time Price,True,1397136600000,4,0.0,0.0,1630503612,1.75,1.76,1.74 - 1.76,1.74,152659,1.75,1.75,0.0,32,361,NasdaqCM,USD,1.75,9285695,3596957,0.805,0.8518519,2.0 - Buy,False,USD,NCM,"Daré Bioscience, Inc.",finmb_423979060,America/New_York,EDT,-14400000,us_market,False,"Dare Bioscience, Inc.",REGULAR,0.945 - 3.85,-2.1,-0.54545456,0.945,3.85,1500508800,1628755203,1636551000,1636983000,-0.789,-0.71,-0.63,-2.777778,0.135,1.5805556,0.16944444,0.10720562,1.6118841,0.13811588,0.08568599,123413504,-2.464789,12.962962,15,0,Daré Bioscience,1.50,65.09%,26.30%,3.8500,0.9450,1.5806,1.6119,9.29M,3.6M,70.52M,,68.86M,3.90%,5.04%,4.79M,0.82,6.95%,6.79%,5.25M,,,,,,0.00%,"Jul 19, 2017",,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-175.69%,-807.19%,,,,-83.33k,-32.85M,-32.52M,-0.7890,,9.11M,0.13,492.46k,6.36,2.34,0.14,-34.72M,-21.58M,Value,92122,Healthcare,16,"DarÃ© Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.",San Diego,858 926 7655,CA,1609372800,United States,http://www.darebioscience.com,86400,3655 Nobel Drive,Biotechnology,Suite 260
